This is the authors' abstract. We don't add key points for this paper.
Creatine (CR) is an essential energy substance that is widely used as a dietary supplement. Currently, industrial-scale biosynthesis of CR remains challenged by its low efficiency and high costs. Here, a cost-effective platform was developed in Corynebacterium glutamicum for high-yield CR production, achieving a remarkable 92.2% reduction in production costs. Through combinatorial enzyme screening and expression regulation, a heterologous pathway consisting of l -arginine: glycine amidinotransferase (AGAT) from Cylindrospermopsis raciborskii and guanidinoacetate methyltransferase (GAMT) from Homo sapiens was established and optimized. Next, implementation of the l -ornithine cycle coordinately enhanced l -arginine carbon fluxes from l -ornithine and alleviated feedback inhibition of l -ornithine for AGAT. Furthermore, an S -adenosyl- l -methionine (SAM) self-supply system was established, achieving a 66.2-fold increase in SAM levels by enhancing the SAM synthetic flux, establishing an adenosine-mediated adenosine-5′-triphosphate (ATP) regeneration cycle, and optimizing the recycling pathways of the byproduct S -adenosyl-homocysteine (SAH). The final strain demonstrated a CR titer of 16.8 g/L in a 5 L bioreactor with a productivity of 0.23 g/(L h), which represented the highest levels reported to date. This study presents a novel cost-effective strategy for CR synthesis through eliminating the reliance on costly and unsustainable substrates.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: